You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Product Development of Intensity Modulation for Bolus Electron Conformal Therapy

    SBC: Decimal, LLC            Topic: 102

    Project Summary/Abstract Objective: This project aims to elevate electron beam therapy (EBT) technology, which provides effective radiation treatment for superficial cancers (depthandlt;6 cm), to that of other external beam radiotherapies (XRT), e.g. x-rays and protons, by bringing electron intensity modulation into the clinic. Challenge: Approximately 10% of radiotherapy patients (173,000 in U ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Drug Eluting Embolization Coils for Improved Treatment of Intracranial Aneurysms

    SBC: Ancure, LLC            Topic: 105

    PROJECT SUMMARY Brain aneurysms are a high-risk condition in which bulging blood vessels in the brain are at risk of rupture. The mortality rate after rupture is 40-60% if no treatment is administered. Current treatment for both ruptured and unruptured aneurysms includes surgical clipping (exovascular therapy) and catheter-based intervention (endovascular therapy). In endovascular therapy, which i ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a small molecule inhibitor of PAI-1 for the treatment of diffuse cutaneous systemic sclerosis

    SBC: MDI THERAPEUTICS INC            Topic: NIAMS

    This project will provide critical preclinical data for a novel therapeutic small molecule inhibitor of plasminogen activator inhibitor 1 (PAI-1) as a potential treatment for diffuse cutaneous systemic sclerosis with associated interstitial lung disease (dcSSc-ILD). SSc is a devastating disease of unknown etiology with no currently approved disease-modifying treatments; lung fibrosis (interstitial ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a novel small molecule-based approach for accelerated fracture repair in the aging skeleton

    SBC: CAYMAN CHEMICAL COMPANY, INCORPORATED            Topic: NIAMS

    PROJECT SUMMARY/ABSTRACT Approximately 6.3 million fractures occur in the United States each year, accounting for 16% of all musculoskeletal injuries and leading to well over 10 million hospital and physician offices visits. Up to 10% of fractures are recalcitrant and require surgical intervention for proper healing. The weakened bones in the growing geriatric population are contributing to the ri ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Bioresorbable Nanoparticles for Visual Detection of Early-Stage Dental Caries

    SBC: GreenMark Biomedical Inc.            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACT This project responds to the need identified by NIDCR to develop improved methods to detect and predict progression of dental caries (tooth decay) to improve human health. Worldwide, caries is the most common chronic disease affecting almost everyone. Dental disease is a major cause of economic and social loss and leads to complications including pain, tooth loss and even ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury

    SBC: Mitovation, Inc.            Topic: 101

    Neonatal hypoxia/ischemia is a known cause of cerebral damage resulting from inadequate blood flow and/or oxygen delivery to the infant brain before, during, or after birth. The occurrence among hospital deliveries is ~2-4 per 1000 full-term births with a drastic increase among premature newborns. The deficit in oxygen delivery to the brain results in extensive damage and severe disabilities. Rest ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)

    SBC: Stemsynergy Therapeutic            Topic: 102

    ABSTRACT Individuals with the rare, inherited disorder Familial Adenomatous Polyposis (FAP) develop thousands of precancerous polyps at an early age and ultimately develop colorectal cancer (CRC). The current standard of care for FAP is colectomy. However, unavoidable side-effects of colectomy are debilitating. Furthermore, colectomy does not prevent subsequent development of extra-colonic intesti ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways

    SBC: COGNITION THERAPEUTICS, INC.            Topic: NIA

    Aβ oligomers are considered the most toxic structural form of Amyloid beta, causing synaptotoxic changes underlying cognitive decline in Alzheimer’s disease. CogRx has developed the world’s first highly brain penetrant drug that selectively displaces oligomers from synaptic receptor sites and clears oligomers from the brain into the cerebrospinal fluid (CSF). This first-in-class drug, CT1812, ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. The Sustainable Heartland Accelerator Regional Partnership (SHARP) Hub

    SBC: BBC ENTREPRENEURIAL TRAINING & CONSULTING LLC            Topic: 500

    Project Summary/Abstract Despite the investment of billions of dollars in biomedical research each year from NIH, barriers remain in effectively translating basic science discoveries from academia to commercial products that benefit patients. These barriers include a funding gap between basic research and commercial developments, a lack of knowledge by innovators on how to bring products to market ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government